肿瘤细胞治疗研究
英文原题：Genitourinary cancers updates: highlights from ASCO 2023.
Genitourinary cancers updates: highlights from ASCO 2023.
免疫治疗和靶向治疗方法的重大科学进展改善了泌尿生殖系统（GU）恶性肿瘤患者的临床结局，并增加了治疗选择。
免疫治疗和靶向治疗方法的重大科学进展改善了临床结局，并为泌尿生殖系统（GU）恶性肿瘤患者增加了治疗选择。我们重点介绍在2023年ASCO年会上发布的临床试验进展，包括用于前列腺癌的PARP抑制剂、用于尿路上皮癌的抗体药物偶联物和成纤维细胞生长因子受体抑制剂，以及用于肾细胞癌的HIF2a抑制剂。双特异性抗体、CAR-T 细胞和放射性药物等新型药物目前处于早期开发阶段，也对GU癌症格局具有很高的潜在影响。随着治疗选择增多，该领域将需要确定最佳治疗顺序，以优化每位患者的结局。
Significant scientific advances in immunotherapy and targeted therapy approaches have improved clinical outcomes and increased treatment options for patients with genitourinary (GU) malignancies. We highlight the clinical trial developments released at the ASCO 2023 annual meeting, including PARP inhibitors for prostate cancer, antibody drug conjugates and fibroblast growth factor receptor inhibitors for urothelial cancer, and HIF2a inhibitors for renal cell carcinoma. Novel agents such as bispecific antibodies, chimeric antigen receptor T-cells, and radiopharmaceuticals are currently in early phase development and also have high potential impact for the GU cancer landscape. With more treatment options, the field will need to define best treatment sequencing to optimize outcomes for each patient.
MEMBER ACCOUNT
登录成功会直接打开下一页。
